5,6-dihydronaphthalene-1-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5,6-dihydronaphthalene-1-carboxylic acid
• 化学式: C₁₁H₁₀O₂
• 分子量: 174.199
• InChiKey: GTYAOOWWEBTZKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5,6-dihydronaphthalene-1-carboxylic acid 在 盐酸 、 间氯过氧苯甲酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 ethyl (trans)-1a,2,3,7b-tetrahydronaphtho-[1,2-b]oxirene-7-carboxylate
  参考文献：
  名称：

  Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968)

  摘要：

  Various racemic and enantioenriched (trans)-X,Y-dihydroxy-X,Y-dihydronaphthoyl analogues as well as X-hydroxy-naphthoyl analogues of CRTh2 antagonist 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido [4,3-b]indol-5(2H)-yl) acetic acid (1, Setipiprant/ACT-129968) were synthesized in order to gain insight into regio- and enantioselectivity of the metabolic oxidation of 1 and to verify the structures of four metabolites that were proposed earlier in a clinical ADME study. Analytical data of the synthetic standards were compared with data from samples of biological origin. The two major metabolites M7 and M9 were unambiguously verified as 2-(2-((trans)-3,4-dihydroxy-3,4-dihydronaphthalene-1-carbony1)- and 242-((trans)-5,6-dihydroxy-5,6-dihydronaphthalene-1-carbonyl)-8-fluoro-3,4-dihydro-1H-pyrido [4,3-b]indol-5 (2H)-yl) acetic acid, respectively, each composed of two enantiomers with 68% and 44% ee in favor of (+)-(3S,4S)-M7 and (+)-(5S,6S)-M9, respectively. Likewise, minor metabolites M3 and M13 were identified as 2-(8-fluoro-2-(5-hydroxy-1-naphthoyl) and 2-(8-fluoro-2-(4-hydroxy-1-naphthoyl)-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-5-yl)acetic acid, respectively.

  DOI：

  10.1021/acs.jmedchem.5b00824
• 作为产物：
  描述：

  1,2,3,4-四氢-1-萘酚 在 正丁基锂 、 甲基磺酰氯 、 三乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 二氯甲烷 、 水 为溶剂， 反应 5.5h， 生成 5,6-dihydronaphthalene-1-carboxylic acid
  参考文献：
  名称：

  Explorations into the Potential of Chiral Sulfonium Reagents to Effect Asymmetric Halonium Additions to Isolated Alkenes

  摘要：

  While methods for the racemic dihalogenation and halohydroxylation of alkenes have been known for decades, enantioselective variants of these processes remain elusive. Initial attempts were made to overcome this long-standing challenge by exploring the potential of chiral, crystalline, sulfur-derived halonium reagents to accomplish the asymmetric dichlorination and iodohydroxylation of 1,2-dihydronaphthalene. Asymmetric dichlorination of this substrate was achieved in 57% yield and 14% enantiomeric excess (ee), but asymmetric iodohydroxylation was much more successful, giving 67% yield and 63% ee. Thorough studies were made of these processes, including investigation of various chiral sulfide derivatives, their substrate scopes, and the reaction conditions.

  DOI：

  10.1055/s-0033-1338865

文献信息

• Supramolecular Control of Selectivity in Hydroformylation of Vinyl Arenes: Easy Access to Valuable β-Aldehyde Intermediates
  作者：Paweł Dydio、Joost N. H. Reek

  DOI：10.1002/anie.201209582

  日期：2013.4.2

  flow! A rationally designed regioselective hydroformylation catalyst, [Rh/L], in which noncovalent ligand–substrate interactions allow the unprecedented reversal of selectivity from the typical α‐aldehyde to the otherwise unfavored product β‐aldehyde, is reported. This catalytic system opens up novel and sustainable synthetic pathways to important intermediates for the fine‐chemicals industry.

  逆流而上！据报道，一种合理设计的区域选择性加氢甲酰化催化剂[Rh / L]，其中非共价配体-底物的相互作用使选择性从典型的α-醛到其他不利的产物β-醛发生了前所未有的逆转。该催化体系为精细化工行业的重要中间体开辟了新的，可持续的合成途径。
• Beyond Classical Reactivity Patterns: Hydroformylation of Vinyl and Allyl Arenes to Valuable β- and γ-Aldehyde Intermediates Using Supramolecular Catalysis
  作者：Paweł Dydio、Remko J. Detz、Bas de Bruin、Joost N. H. Reek

  DOI：10.1021/ja503033q

  日期：2014.6.11

  regioselective hydroformylation of vinyl and allyl arenes bearing an anionic group. In principle, the binding site of the ligand is used to preorganize a substrate molecule through noncovalent interactions with its anionic group to promote otherwise unfavorable reaction pathways. We demonstrate that this strategy allows for unprecedented reversal of selectivity to form otherwise disfavored β-aldehyde products

  在这项研究中，我们报告了一系列双膦和双亚磷酸酯 L1-L7 配体的铑配合物的性质，它们配备了完整的阴离子结合位点（DIM 口袋），以及它们在乙烯基和烯丙基芳烃的区域选择性加氢甲酰化中的应用带有阴离子基团。原则上，配体的结合位点用于通过与其阴离子基团的非共价相互作用预先组织底物分子，以促进其他不利的反应途径。我们证明，这种策略允许在乙烯基 2- 和 3- 羧基芳烃的加氢甲酰化中形成前所未有的选择性逆转，以形成其他不受欢迎的 β-醛产物，化学和区域选择性高达 100%。该催化剂具有广泛的底物范围，包括具有内部双键的最具挑战性的底物。在催化相关条件下催化剂的配位研究揭示了氢化双羰基铑配合物 [Rh(Ln)(CO)2H] 的形成。滴定研究证实，铑配合物可以结合配体的 DIM 结合位点中的阴离子物质。此外，对最活性催化剂的动力学研究和原位光谱研究可以深入了解系统的操作模式，并揭示催化活性物质与不寻常
• Aminoethanol derivatives
  申请人：——

  公开号：US20040127574A1

  公开（公告）日：2004-07-01

  The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula 1 wherein Ar 1 is an aromatic ring group optionally having substituents, Ar 2 is an aromatic ring group having substituents, OR″ is an optionally protected hydroxyl group, R is an acyl group, R′ is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.

  本发明提供了一种具有胆固醇酯转移蛋白抑制作用的药物剂，可用作降低血脂等方面的药物。本发明涉及一种由式1表示的化合物，其中Ar1是一个带有取代基的芳香环基团，Ar2是一个带有取代基的芳香环基团，OR″是一个可选保护的羟基，R是一个酰基，R′是一个氢原子或一个可选带有取代基的碳氢基团，或其盐，以及含有式(I)的化合物或其盐或前药的药物组合物。
• AMINOETHANOL DERIVATIVES
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1362846A1

  公开（公告）日：2003-11-19

  The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula wherein Ar1 is an aromatic ring group optionally having substituents, Ar2 is an aromatic ring group having substituents, OR'' is an optionally protected hydroxyl group, R is an acyl group, R' is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.

  本发明提供了一种具有胆固醇酯转移蛋白抑制作用的药剂，可用作降血脂药等。本发明涉及一种由式表示的化合物 其中 Ar1 是可选具有取代基的芳香环基，Ar2 是可选具有取代基的芳香环基，OR''是可选保护的羟基，R 是酰基，R'是氢原子或可选具有取代基的烃基，或其盐，以及含有式（I）化合物或其盐或其原药的药物组合物。
• EP1362846
  申请人：——

  公开号：——

  公开（公告）日：——